Company Profile
CEO
Mr. David A. Ricks(Chairman & CEO)
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
50.0K
Beta
0.52
Forward P/E
26.2
52W High
$1182.73
52W Low
$623.78
Profit Margin
35.0%
Operating Margin
49.4%
Return on Equity
107.5%
Revenue Growth
55.5%
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalo...
Valuation
Market Cap$1.02T
P/E (TTM)40.84
P/S (TTM)12.93
EV/EBITDA--
Cash Flow
FCF Yield+0.6%
SBC Adj. FCF Yield+0.6%
SBC Impact10.1%
Margins & Growth
Profit Margin37.4%
Operating Margin--
Revenue YoY55.5%
Earnings YoY168.1%
Balance
Cash$5.28B
Debt$39.37B
Net Cash$-34.09B
Dividend
Dividend Yield0.60%
Payout Ratio20.9%
Quarterly Payout$1.55B